CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- 4 Open-market sale Director sold 26,736 shares at an average $95.27 ($2,547,035)
- 4 Open-market sale Director sold 1,000 shares at $91.48 ($91,480)
- 4 Open-market sale Chief Financial Officer sold 1,655 shares at an average $89.58 ($148,247)
- 4 Open-market sale Director sold 7,021 shares at an average $87.84 ($616,708)
- 4 Open-market sale Senior VP, R&D sold 3,005 shares at an average $90.40 ($271,645)
- 4 Open-market sale Director sold 10,000 shares at $93.39 ($933,900)
- 4 Open-market sale Chief Executive Officer sold 14,490 shares at an average $89.84 ($1,301,793)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Financial Officer acquired 4,686 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 18,583 shares (grant or award)
- 4 Grant or award Senior VP, R&D acquired 3,216 shares (grant or award)
- 4 Open-market sale Chief Executive Officer sold 15,210 shares at an average $90.41 ($1,375,074)
- 4 Open-market sale Chief Financial Officer sold 1,100 shares at an average $86.22 ($94,837)
- 4 Open-market sale Senior VP, R&D sold 195 shares at $86.60 ($16,887)
- 4 Open-market sale Director sold 4,455 shares at an average $92.81 ($413,455)
- 4 Open-market sale Director sold 4,000 shares at an average $98.70 ($394,793)
- 4 Shares withheld for taxes Senior VP, R&D gave up 295 shares (to pay taxes)
- 4 Exercise or conversion Chief Financial Officer acquired 3,957 shares (option exercise)
- 4 Open-market sale Chief Executive Officer sold 3,600 shares at an average $82.89 ($298,390)
Page 15 of 34 · 669 filings